Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

March 2, 2027

Conditions

Peripheral T Cell LymphomaEpigenetic Repression

Interventions

DRUG

Chidamide

chidamide 30mg biw, p.o, 21 days for a cycle.

DRUG

Azacitidine

75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.

DRUG

liposomal mitoxantrone

12mg/m2， d1,21 days for a cycle.

DRUG

prednisone

60mg/m2，d1-5,21 days for a cycle.

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER